NASDAQ:MORF Morphic (MORF) Stock Price, News & Analysis → get a piece of the profit from this land (From True Market Insiders) (Ad) Free MORF Stock Alerts $29.23 -3.22 (-9.92%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$28.93▼$32.7050-Day Range$27.27▼$36.8952-Week Range$19.34▼$63.08Volume420,858 shsAverage Volume508,632 shsMarket Capitalization$1.46 billionP/E RatioN/ADividend YieldN/APrice Target$51.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Morphic alerts: Email Address Morphic MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside76.2% Upside$51.50 Price TargetShort InterestBearish12.82% of Shares Sold ShortDividend StrengthN/ASustainability-0.57Upright™ Environmental ScoreNews Sentiment0.34Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($4.07) to ($4.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.66 out of 5 starsMedical Sector226th out of 919 stocksPharmaceutical Preparations Industry96th out of 422 stocks 3.3 Analyst's Opinion Consensus RatingMorphic has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageMorphic has received no research coverage in the past 90 days.Read more about Morphic's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.82% of the outstanding shares of Morphic have been sold short.Short Interest Ratio / Days to CoverMorphic has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.Change versus previous monthShort interest in Morphic has recently increased by 2.72%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMorphic does not currently pay a dividend.Dividend GrowthMorphic does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMorphic has received a 76.58% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Morphic is -0.57. Previous Next 2.4 News and Social Media Coverage News SentimentMorphic has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Morphic this week, compared to 2 articles on an average week.Search Interest1 people have searched for MORF on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Morphic to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Morphic insiders have not sold or bought any company stock.Percentage Held by Insiders28.10% of the stock of Morphic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.25% of the stock of Morphic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Morphic's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Morphic are expected to decrease in the coming year, from ($4.07) to ($4.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Morphic is -8.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Morphic is -8.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMorphic has a P/B Ratio of 2.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Morphic's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About Morphic Stock (NASDAQ:MORF)Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Read More MORF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MORF Stock News HeadlinesMay 15 at 6:55 AM | seekingalpha.comMORF Morphic Holding, Inc.May 9, 2024 | finance.yahoo.comMorphic to Participate in RBC Capital Markets Global Healthcare ConferenceApril 26, 2024 | markets.businessinsider.comMorphic Holding’s Financial Strength and Promising MORF-057 Clinical Trials Spur Buy RatingApril 26, 2024 | markets.businessinsider.comMorphic Holding’s Buy Rating Affirmed: Promising Trials and Strong Financial OutlookApril 25, 2024 | finance.yahoo.comMorphic Holding Inc (MORF) Q1 2024 Earnings: A Detailed ReviewApril 25, 2024 | globenewswire.comMorphic Announces Corporate Highlights and Financial Results for the First Quarter 2024April 2, 2024 | prnewswire.comAdemi LLP Investigates Claims of Securities Fraud against Morphic Holding, Inc.March 26, 2024 | businesswire.comMorphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsMarch 22, 2024 | insidermonkey.comBillionaire Steve Cohen and Insiders are Buying These 5 StocksMarch 19, 2024 | finanznachrichten.deMorphic Therapeutic: Morphic Appoints Dr. Simon Cooper as Chief Medical OfficerMarch 19, 2024 | markets.businessinsider.comMorphic Appoints Simon Cooper As Chief Medical OfficerMarch 19, 2024 | globenewswire.comMorphic Appoints Dr. Simon Cooper as Chief Medical OfficerMarch 17, 2024 | finance.yahoo.comMORF Jul 2024 17.500 putMarch 16, 2024 | finance.yahoo.comMORF Apr 2024 50.000 callMarch 16, 2024 | finance.yahoo.comMORF Apr 2024 20.000 putMarch 16, 2024 | finance.yahoo.comMORF Jul 2024 40.000 callMarch 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Morphic Holding (MORF)March 8, 2024 | markets.businessinsider.comMorphic Holding: Strong Financials and Promising Clinical Trials Reinforce Buy RatingMarch 5, 2024 | globenewswire.comMorphic to Participate in March Investor ConferencesMarch 3, 2024 | ca.finance.yahoo.comMORF Jul 2024 30.000 callFebruary 26, 2024 | markets.businessinsider.comMorphic Holding’s Strong Clinical Progress and Financial Stability Support Buy RatingFebruary 26, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Celldex (CLDX), Abbott Labs (ABT) and Morphic Holding (MORF)February 23, 2024 | markets.businessinsider.comMorphic Holding’s Buy Rating Affirmed on Strong Clinical and Financial ProspectsFebruary 22, 2024 | finanznachrichten.deMorphic Therapeutic: Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023February 22, 2024 | benzinga.comRecap: Morphic Holding Q4 EarningsSee More Headlines Receive MORF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Morphic and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/25/2024Today5/18/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MORF CUSIPN/A CIK1679363 Webwww.morphictx.com Phone(781) 996-0955FaxN/AEmployees121Year FoundedN/APrice Target and Rating Average Stock Price Target$51.50 High Stock Price Target$75.00 Low Stock Price Target$33.00 Potential Upside/Downside+76.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-152,100,000.00 Net MarginsN/A Pretax Margin-29,119.96% Return on Equity-22.93% Return on Assets-22.26% Debt Debt-to-Equity RatioN/A Current Ratio38.17 Quick Ratio38.17 Sales & Book Value Annual Sales$520,000.00 Price / Sales2,815.64 Cash FlowN/A Price / Cash FlowN/A Book Value$13.25 per share Price / Book2.21Miscellaneous Outstanding Shares50,090,000Free Float36,018,000Market Cap$1.46 billion OptionableOptionable Beta1.48 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Bruce N. Rogers Ph.D. (Age 55)President & Interim Principal Executive Officer Comp: $787.88kDr. Timothy A. Springer Ph.D. (Age 76)Founder, Independent Director & Member of Scientific Advisory Board Comp: $40kDr. Marc Schegerin M.B.A. (Age 48)M.D., CFO & COO Comp: $722.38kDr. Praveen P. Tipirneni M.D. (Age 55)CEO, MD & Director (Leave of Absence) Comp: $991.33kMr. Robert E. Farrell Jr. (Age 59)CPA, Senior VP of Finance & Chief Accounting Officer Dr. Blaise Lippa Ph.D.Chief Scientific OfficerMr. William D. DeVaul Esq. (Age 53)General Counsel & Secretary Comp: $601.44kMr. Aaron PeltaSenior Vice President of Business & Corporate DevelopmentMs. Joanne GibbonsSenior Vice President of Regulatory AffairsDr. Simon Cooper MBBS (Age 54)Chief Medical Officer More ExecutivesKey CompetitorsPacira BioSciencesNASDAQ:PCRXAkero TherapeuticsNASDAQ:AKRODynavax TechnologiesNASDAQ:DVAXANI PharmaceuticalsNASDAQ:ANIPDay One BiopharmaceuticalsNASDAQ:DAWNView All CompetitorsInsiders & InstitutionsArtal Group S.A.Bought 75,000 shares on 5/17/2024Ownership: 4.418%California State Teachers Retirement SystemSold 986 shares on 5/16/2024Ownership: 0.061%Price T Rowe Associates Inc. MDBought 300,958 shares on 5/15/2024Ownership: 5.038%Affinity Asset Advisors LLCBought 182,330 shares on 5/15/2024Ownership: 0.449%LRI Investments LLCBought 1,000 shares on 5/15/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions MORF Stock Analysis - Frequently Asked Questions Should I buy or sell Morphic stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Morphic in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MORF shares. View MORF analyst ratings or view top-rated stocks. What is Morphic's stock price target for 2024? 6 Wall Street research analysts have issued twelve-month price objectives for Morphic's stock. Their MORF share price targets range from $33.00 to $75.00. On average, they anticipate the company's stock price to reach $51.50 in the next year. This suggests a possible upside of 76.2% from the stock's current price. View analysts price targets for MORF or view top-rated stocks among Wall Street analysts. How have MORF shares performed in 2024? Morphic's stock was trading at $28.88 at the beginning of the year. Since then, MORF stock has increased by 1.2% and is now trading at $29.23. View the best growth stocks for 2024 here. When is Morphic's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our MORF earnings forecast. How were Morphic's earnings last quarter? Morphic Holding, Inc. (NASDAQ:MORF) issued its quarterly earnings results on Thursday, April, 25th. The company reported ($0.91) earnings per share for the quarter, beating analysts' consensus estimates of ($0.96) by $0.05. What ETF holds Morphic's stock? ALPS Medical Breakthroughs ETF holds 35,018 shares of MORF stock, representing 0.95% of its portfolio. What other stocks do shareholders of Morphic own? Based on aggregate information from My MarketBeat watchlists, some companies that other Morphic investors own include Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), AVEO Pharmaceuticals (AVEO), Atreca (BCEL), CymaBay Therapeutics (CBAY), Chiasma (CHMA), Clovis Oncology (CLVS), Gritstone bio (GRTS), Idera Pharmaceuticals (IDRA) and Kaleido Biosciences (KLDO). When did Morphic IPO? Morphic (MORF) raised $75 million in an IPO on Thursday, June 27th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO. Who are Morphic's major shareholders? Morphic's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (5.04%), Vanguard Group Inc. (4.51%), Artal Group S.A. (4.42%), Affinity Asset Advisors LLC (0.45%), Assenagon Asset Management S.A. (0.14%) and Swiss National Bank (0.12%). Insiders that own company stock include Amir Nashat, Bruce Rogers, Joseph P Slattery, Marc Schegerin, Peter Linde, Praveen P Tipirneni, Robert E Farrell Jr, Robert E Farrell, Jr, Timothy A Springer, Timothy A Springer and William Devaul. View institutional ownership trends. How do I buy shares of Morphic? Shares of MORF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MORF) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsBill Clinton Backing Biden Replacement???The Freeport SocietyI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Morphic Holding, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.